TargetMol

Agomelatine

Product Code:
 
TAR-T1445
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T1445-5mg5mg£116.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1445-1mL1 mL * 10 mM (in DMSO)£121.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1445-10mg10mg£132.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1445-25mg25mg£185.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1445-50mg50mg£270.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1445-100mg100mg£330.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1445-500mg500mg£703.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Agomelatine is structurally closely related to melatonin. Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, tested in an animal model of depression.
CAS:
138112-76-2
Formula:
C15H17NO2
Molecular Weight:
243.306
Pathway:
GPCR/G Protein; Neuroscience
Purity:
0.9986
SMILES:
COc1ccc2cccc(CCNC(C)=O)c2c1
Target:
Melatonin Receptor; 5-HT Receptor

References

1. Dagyt? G, et al. Behav Brain Res, 2011, 218(1), 121-128. 2. Barden N, et al. Prog Neuropsychopharmacol Biol Psychiatry, 2005, 29(6), 908-916. 3. Soumier A, et al. Neuropsychopharmacology, 2009, 34(11), 2390-2403. 4. Millan MJ, et al. Psychopharmacology (Berl), 2005, 177(4), 448-458. 5. Banasr M, et al. Biol Psychiatry, 2006, 59(11), 1087-1096.